Our findings raise the question of whether fluctuations in serum CEACAM5 reflect EMT and rEMT processes in both primary tumors and metastatic sites, contributing to cancer dissemination and drug resistance under EGFR‐TKI treatment. Here, CEACAM5 is linked to cancer.